{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"EP_1605042_A2","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"107-907-516-024-51X","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11663,"type":"PATENT","title":"University of Montreal - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":2579,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8327,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:uni* montreal
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 1939
Search Applicants and Owners separately:uni* montreal
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 1939
(a) a first fusion product comprising:(1) a first fragment of a first molecule whose fragments can exhibit a detectable activity when associated and(2) a first protein-protein interacting domain;
(b) a second fusion product comprising:(1) a second fragment of said first molecule and(2) a second protein-protein interacting domain that can bind said first protein-protein interacting domain; and
(c) both (a) and (b)."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The composition according to claim 5, wherein said first molecule is a protein:"],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The composition according to claim 6, wherein said first molecule is selected from the group consisting of:
(a) murine dihydrofolate reductase;
(b) Streptomyces tyrosinase copper binding subunit Melc1;
(c) glutathione-S-transferase;
(d) green fluorescent protein;
(e) fire fly luciferase;
(f) xanthine-guanine phosphoribosyl transferase;
(g) adenosine deaminase;
(h) bleomycin binding protein;
(i) hygromycin-B-phosphotransferase;
(j) L-histidinol NAD+ oxidoreductase;
(k) aminoglycoside kinase."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The composition according to any one of claims 5 to 7, wherein said first fragment is mutated and differs from the corresponding wild-type sequence by at least one amino acid."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The composition according to any one of claims 5 to 8, wherein said detectable activity is an optically-detectable signal."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The composition according to claim 9 wherein said optically-detectable signal comprises photoluminescence or fluorescence."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The composition according to any one of claims 1 to 4, comprising a product selected from the group consisting of:
(a) a first fusion product comprising:(1) a first fragment of a first molecule whose fragments can exhibit a detectable activity when associated and(2) a second molecule that can bind said first fragment;
(b) a second fusion product comprising:(1) a second fragment of said first molecule and(2) a third molecule that can bind said second fragment; and
(c) both (a) and (b)."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The composition according to claim 11 wherein the second and third molecules can bind to each other."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The composition according to claim 1 comprising a product selected from the group consisting of:
(a) a first fusion product comprising:1) a first fragment of a first protein molecule whose fragments exhibit a detectable activity when associated, and2) a second molecule that is fused to said first fragment;
(b) a second fusion product comprising1) a second fragment of said first protein molecule, and2) a third molecule that is fused to said second fragment; and
(c) both (a) and (b)."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The composition according to any one of claims 11 to 13 wherein said first molecule is selected from the group consisting of:
(a) murine dihydrofolate reductase;
(b) herpes simplex virus thymidine kinase."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["A composition comprising a nucleic acid molecule encoding a fusion product, wherein said molecule comprises sequences encoding the product defined in any of claims 5 to 10."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["A composition comprising a nucleic acid molecule encoding a fusion product, wherein said molecule comprises sequences encoding the product defined in any of claims 11 to 15."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The composition according to any one of claims 1 to 14, wherein said complementary fragments of a first molecule, each fused to separate molecules, are purified PCA fragment fusion proteins."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The composition according to any one of claims 5 to 14, wherein the fusion products are purified PCA fragment-fusion proteins."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["A diagnostic kit comprising the composition according to any one of claims 17 to 18."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["A host cell comprising a composition according to any one of claims 1 to 18."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["Use of the composition of any one of claims 1 to 18 (or the host cell of claim 20) for
(a) functional testing of novel genes;
(b) screening of natural products for pharmacological activity;
(c) screening of compound libraries for pharmacological activity;
(d) screening of cDNA libraries for protein-protein interactions;
(e) screening of novel, induced protein-molecular associations between a target protein and an expression library;
(f) distinguishing induced versus constitutive protein-protein interactions;
(g) identification of novel gene products that interact with DNA, RNA or carbohydrates;
(h) identification of enzyme substrates and small molecule inhibitors of enzymes;
(i) determining equilibrium or kinetic parameters for a specific protein-protein interaction;
(j) determining kinetics of protein assembly in cells;
(k) detecting enzyme-substrate interactions;"],"number":21,"annotation":false,"claim":true,"title":false},{"lines":["The use according to claim 20(d) wherein reconstitution of protein activity is detected."],"number":22,"annotation":false,"claim":true,"title":false},{"lines":["The use according to claim 20(j) wherein time-dependent reconstitution of activity of said first molecule is detected."],"number":23,"annotation":false,"claim":true,"title":false},{"lines":["Use of the composition of any one of claims 11 to 14 and 16 to 18 for
(a) detection of multiple protein complexes;
(b) detection of protein-DNA complexes;
(c) detection of protein-RNA complexes;
(d) detection of induced protein complexes;
(e) detection of protein-drug complexes;
(f) screening combinatorial libraries of compounds for those that induce protein-protein, protein-DNA or protein-RNA complexes;"],"number":24,"annotation":false,"claim":true,"title":false},{"lines":["The use of any one of claims 21 to 24, wherein said composition or said host cell is a component in a protein fragment complementation assay for the detection of molecular interactions."],"number":25,"annotation":false,"claim":true,"title":false},{"lines":["The use of claim 25 wherein said molecular interactions are protein-protein interactions."],"number":26,"annotation":false,"claim":true,"title":false},{"lines":["The use according to any one of claims 21 to 26, wherein a chromogenic, fluorogenic, enzymatic, cell survival assay or other detectable signal is generated."],"number":27,"annotation":false,"claim":true,"title":false},{"lines":["The use according to any one of claims 21 to 26, wherein said use comprises:
(a) selecting an appropriate protein reporter molecule;
(b) effecting fragmentation of said protein reporter molecule;
(c) fusing or attaching fragments of said protein reporter molecule separately to other molecules; followed by
(d) reassociation of said reporter fragments through interactions of the molecules that are fused to said fragments; and
(e) detecting molecular interactions by reconstitution of protein activity."],"number":28,"annotation":false,"claim":true,"title":false},{"lines":["The use according to claim 28, wherein:
(a) said reporter molecule is selected from the group consisting of a protein, a fluorescent protein, a luminescent protein and a phosphorescent protein;
(b) fragmentation of said reporter molecule results in reversible loss of reporter function."],"number":29,"annotation":false,"claim":true,"title":false},{"lines":["The use according to any one of claims 21 to 26, wherein said first molecule is an enzyme having a molecular weight of 10 to 40 kDa."],"number":30,"annotation":false,"claim":true,"title":false},{"lines":["The use according to any one of claims 21 to 26, wherein said first molecule is a monomeric protein and wherein said use comprises reassembly of separate fragments of said monomeric protein operated by the interaction of molecular domains fused to each of said separate fragments, reassembly of said separate fragments independently of other molecular processes and detection of said reassembly by means of reconstitution of activity of said protein."],"number":31,"annotation":false,"claim":true,"title":false},{"lines":["The use according to any one of claims 21 to 26, wherein said fragments of a first molecule have no detectable activity in the absence of said fused interacting domains."],"number":32,"annotation":false,"claim":true,"title":false},{"lines":["Use of the composition according to any one of claims 1 to 18 for the manufacture of a medicament for use in gene therapy of mammalian disease."],"number":33,"annotation":false,"claim":true,"title":false},{"lines":["Use of the composition according to any one of claims 1 to 18 for the manufacture of a medicament for treatment of cancer."],"number":34,"annotation":false,"claim":true,"title":false},{"lines":["The use according to claim 34 wherein said cancer is selected from the group consisting of breast cancer and adenocarcinoma."],"number":35,"annotation":false,"claim":true,"title":false},{"lines":["A method for detecting biomolecular interactions, said method comprising:
(a) selecting an appropriate protein reporter molecule;
(b) effecting fragmentation of said protein reporter molecule such that said fragmentation results in reversible loss of reporter function;
(c) fusing or attaching fragments of said protein reporter molecule separately to other molecules;
(d) reassociating said protein reporter fragments through interactions of the molecules that are fused or attached to said fragments; and
(e) detecting the activity of said an appropriate protein reporter molecule."],"number":36,"annotation":false,"claim":true,"title":false},{"lines":["A method of testing detecting biomolecular interactions comprising:
(a) generating a first fusion product comprising:i) a first fragment of a first protein molecule, andii) a second molecule which is different from said first molecule
(b) generating a second fusion product comprising:i) a second protein fragment of said first protein molecule, andii) a third molecule which is different from said first molecule or second molecule;
(c) allowing the first and second fusion products to contact each other; and
(d) testing for activity regained by association of the protein fragments of the first molecule; wherein said association is mediated by interaction of the second and third molecules."],"number":37,"annotation":false,"claim":true,"title":false},{"lines":["A method comprising an assay where fragments of a first protein molecule are fused to a second molecule and fragment association is detected by reconstitution of the first protein molecule's activity."],"number":38,"annotation":false,"claim":true,"title":false},{"lines":["A method of testing for biomolecular interactions, said method comprising the steps of:
1) creating a fusion ofa) a first fragment of a first protein molecule whose fragments can exhibit a detectable activity when associated, andb) a first protein-protein interacting domain;
2) creating a fusion ofa) a second fragment of said first protein molecule, andb) a second or third protein-protein interacting domain that can bind said first protein-protein interacting domain,
3) allowing the fusions of (1) and (2) to contact each other, and
4) testing for reconstitution of said protein activity."],"number":39,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}